Covid and JNJ earnings Q4 2021


The Janssen Johnson & Johnson COVID-19 vaccine.

Allen J. Schaben | Los Angeles Times | Getty Images

Johnson & Johnson on Tuesday projected that its Covid vaccine would generate $3 billion to $3.5 billion in sales in 2022, after posting a mixed fourth-quarter report that slightly beat on earnings estimates but missed on revenue.

Here’s how J&J performed compared with what Wall Street expected, based on analysts’ average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.13, vs. $2.12 expected.
  • Revenue: $24.8 billion, vs. $25.29 billion expected

On an unadjusted basis, J&J’s fourth-quarter profit surged to $4.74 billion, almost triple the $1.74 billion it earned during the same quarter the…

Source cnbc.com

0 0 votes
Article Rating

Home prices surged in November, but at a slower rate, S&P Case-Shiller says

Previous article

‘Take a chill pill, stay long’ — Anthony Scaramucci says bitcoin’s recent plunge won’t last

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Earnings